News

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s only viral vector Contract Development and Manufacturing Organisation (CDMO), today announced its participation in BioJapan 2026, one…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in the Alliance for Regenerative Medicine’s (ARM) Cell and Gene Meeting on the Mesa…

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the Therapeutic Goods Administration (TGA) has…

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s only commercial viral vector Contract Development and Manufacturing Organisation (CDMO) and Optosleep, an emerging startup involving researchers…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) and Mirugen Pty Ltd (Mirugen) have co-signed a Letter of Intent (LoI) to collaborate on the evaluation and…

Viral Vector Manufacturing Facility Pty. Ltd. (“VVMF”, “the Company”) has adopted a Diversity Policy. This Policy requires disclosure regarding: The VVMF Board of Directors (“Board”)…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in the American Society of Gene and Cell Therapy’s annual meeting, taking place 11…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in ARM’s Cell and Gene Meeting on the Med 2026, taking place 28 –…

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at Advanced Therapies Week 2026, 9 – 12 February 2026, in San Diego, USA. VVMF…

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), has commenced a strategic collaboration with OXB…

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first and only clinical and commercial-scale viral vector Contract Development and Manufacturing Organisation (CDMO), was officially opened…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) and Chimeric Therapeutics (ASX:CHM, “Chimeric”) have cosigned a Letter of Intent (LOI) to enter a strategic supplier relationship…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at the Cell & Gene Meeting on the Mesa 2025, October 6-8 2025, at the…

Viral Vector Manufacturing Facility Pty. Ltd. (“VVMF”, “the Company”) has adopted aDiversity Policy. This Policy requires disclosure regarding: The VVMF Board of Directors (“Board”) has…

Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) and Cell Therapies Pty Ltd. have co-signed a memorandum of understanding (MoU) to explore strategic collaboration opportunities aimed…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at the Bio International Conference 2025, June 16-19 2025, at the Boston Convention & Exhibition…

Viral Vector Manufacturing Facility Pty Ltd (VVMF) is set to participate in BIO KOREA 2025, May 7-9 2025, bringing its expertise in viral vector manufacturing…

Viral Vector Manufacturing Facility Pty. Ltd. (“VVMF”, “the Company”) has adopted a Diversity Policy. This Policy requires disclosure regarding: The VVMF Board of Directors (“Board”)…

The Viral Vector Manufacturing Facility Pty Ltd (VVMF) is delighted to announce the following appointments to the Board. Sue MacLeman: VVMF Board Chair and Non-Executive…

The Viral Vector Manufacturing Facility Pty Ltd (VVMF) Board is delighted to announce the appointment of Mr. Stephen Thompson as the inaugural Chief Executive Officer…